The Use of Proton Pump Inhibitors Among Adults in Norway—A Nationwide Drug Utilization Study
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Reidar Fossmark und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Drug Utilization, Practice Patterns, Physicians'. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norges Teknisk-Naturvitenskapelige Universitet.
Abstract (Originalsprache)
The use of proton pump inhibitors (PPIs) has increased in Western countries over several decades, and there is concern about unsubstantiated indications and effects of long‐term use. The study aimed to describe the prevalence, incidence, indications, and prescription pattern for PPIs over the past decade in an entire national cohort. This nationwide drug utilization study used data from the Norwegian Prescription Database and Norwegian Patient Registry. Patterns of PPI use were investigated from 2009 to 2022. Prevalent, long‐term, and incident PPI use were calculated. The indication for PPI was defined by the diagnosis code linked to each prescription. Upper endoscopies during the study period were assessed for incident PPI users. PPI prescription increased from 58.1 mill DDD in 2009 to 166.9 mill DDD in 2022, that is, 43 and 106 DDD/1000 inhabitants/day. Prevalent PPI use increased from 3.5% to 9.9%, paralleling an increased incidence from 2.9% to 5.4%. The dominant indications in 2009 and 2022 were esophageal disease in primary care (72.5% and 57.6% of total DDDs) and GERD in specialist care (10.7% and 4.7% of total DDDs). Musculoskeletal disorders, pain, and ulcer prophylaxis all increased during the period. Upper endoscopy around incident PPI use decreased from 25.3% to 11.1%. In conclusion, the 2.46‐fold increase in prevalent PPI use was caused by an absolute increase in PPI prescribed against esophageal disease and GERD, and prophylaxis in patients using ulcerogenic comedication, mainly prescribed in primary care. The findings may help inform strategies to reduce a probable overuse of PPIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Oslo University Hospital, Oslo, Norway.
- Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
- Department of Gastroenterology and Hepatology, St. Olav's University Hospital, Trondheim, Norway.
- Unit of Applied Clinical Research, Department of Public Health and Nursing, Faculty of Medicine and Health Science, Norwegian University of Science and Technology, Trondheim, Norway.
- Department of Clinical Pharmacology, St. Olav's University Hospital, Trondheim, Norway.
ORCID-Profile: Reidar Fossmark, Olav Spigset
Förderung
- Norges Teknisk-Naturvitenskapelige Universitet
Zitieren
APA
Fossmark, R., Molnes, S., Sagatun, L., Salvesen, Ø., & Spigset, O. (2025). The Use of Proton Pump Inhibitors Among Adults in Norway—A Nationwide Drug Utilization Study. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70182
Vancouver
Fossmark R, Molnes S, Sagatun L, Salvesen Ø, Spigset O. The Use of Proton Pump Inhibitors Among Adults in Norway—A Nationwide Drug Utilization Study. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70182
BibTeX
@article{Fossmark2025,
author = {Fossmark, Reidar and Molnes, Sveinung and Sagatun, Liv and Salvesen, Øyvind and Spigset, Olav},
title = {The Use of Proton Pump Inhibitors Among Adults in Norway—A Nationwide Drug Utilization Study},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70182}
}
EUVIMED